BridgeBio Pharma, Inc.
encaleret
autosomal dominant hypocalcemia type 1 (ADH1)
Resolved
56days ago
Phase 2 readout · ~ May 12, 2026 estimated
What's at stake
Phase 2 trial results for encaleret in autosomal dominant hypocalcemia type 1 (ADH1) are due ~ May 12, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 17h ago
“Phase 2 proof-of-principle study and FDA End of Phase 2 interaction completed Phase 3 study to be initiated in 2H 2026”